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episodes), condition speciﬁc quality of life (Incontinence Quality
of Life Questionnaire (I-QOL)), and SF-6D preference scores were
measured at enrollment and 24weeks after treatmentwith a single
injection of botulinum toxin type A or placebo. We measured the
correlation between SF-6D, I-QOL and UI episode change scores.
We used multiple linear regressions to estimate the impact on
SF-6D scores of 50%; 50%–99% and 100% reductions in UI
episodes and a 10-point improvement in I-QOL. These thresholds
are thought to be clinically signiﬁcant and are often reported as
trial outcomes. RESULTS: SF-6D change scores between enroll-
ment and 24 weeks were moderately correlated with I-QOL
change scores (rho = 0.41; p < 0.01) but non-signiﬁcantly corre-
lated with UI episode changes scores (rho = -0.19; p = 0.20). At
24weeks, mean (95%CI) daily UI episodes fell by 0.85 (0.04, 1.3)
and mean I-QOL scores improved by 18 (12, 24). SF-6D scores
increased by 0.03 (0.003, 0.058), due, primarily, to improvements
in the role limitations domains. A50% reduction in UI episodes
was achieved by 49% of patients and corresponded to a 0.09
(0.02, 0.16) SF-6D increase. A  10-point increase in I-QOL was
attained by 65% of patients and was associated with a 0.05
(-0.02, 0.12) SF-6D increase. CONCLUSIONS: These estimates
provide preliminary data for decision analysts wishing to map UI
outcomes to preference scores. The results demonstrate that clini-
cally important changes in condition speciﬁc quality of life are
reﬂected in SF-6D preference scores.
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OBJECTIVES: A randomized clinical trial (TIMES) demon-
strated that combination therapy with tolterodine extended
release (ER) plus tamsulosin for 12 weeks provides clinical ben-
eﬁts over monotherapy with either agent or placebo in men with
moderate to severe lower urinary tract symptoms (LUTS) and
overactive bladder. However, the TIMES study did not report
the impact of these therapies on utility. We developed a statisti-
cal model to predict the utility and quality-adjusted life-years
(QALYs) associated with the various TIMES therapies.
METHODS: The statistical model was developed using urinary
tract symptoms and quality of life (SF-12) data collected from
9416 males participating as part of a separate epidemiologic
survey (EpiLUTS). The model was a multinomial regression,
which predicted the level of responses to each of the 12 domains
of the SF-12. The predictors were daytime and nighttime urinary
frequency, urgency episodes, urge incontinence and International
Prostate Symptom Scores (IPSS). This regression was then used
to predict SF-12 scores of the TIMES patients, based on the
observed mean symptoms values in this study. Next, based on
published regression algorithms, these predicted SF-12 answers
were transformed into EQ-5D utility scores, from which QALYs
were calculated. RESULTS: IPSS score and number of urgency
episodes in 24 hours had the strongest impact on overall utility,
whereas nighttime and especially daytime micturition frequency
had less impact. At week 12, utility scores for placebo, toltero-
dine monotherapy, tamsulosin monotherapy, and combination
therapy were 0.657, 0.684, 0.679 and 0.701, respectively. Cor-
responding QALYs over 12 weeks were 0.143, 0.146, 0.146 and
0.148. Thus, combination therapy resulted in the highest incre-
mental QALYs, saving 0.005 QALYs vs. placebo, 0.002 vs.
tolterodine, and 0.003 vs. tamsulosin. CONCLUSIONS: Com-
bination therapy with tolterodine ER plus tamsulosin results in
the highest predicted utility and QALY gains compared to
placebo or monotherapy with either agent.
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OBJECTIVES: To assess the validity of the Urinary Sensation
Scale (USS) in women with overactive bladder (OAB) and men
with OAB and prostate symptoms (OAB-BPH). METHODS:
Data from 2 clinical trials of tolterodine treatment for OAB were
used to assess the validity of the USS, a 5-point rating scale to
assess the amount of urinary urgency associated with each uri-
nation. The USS ranges from “No feeling of urgency: I could
continue activities until I chose to use the bathroom” to “Unable
to hold; leak urine: I had a wetting accident before arriving at the
bathroom.” The USS was administered with a daily bladder diary
in the 2 trials. Two methods to evaluate the USS are to calculate
a mean urgency score (Mean USS) of all voids or to sum all
urgency ratings (Sum USS). Concurrent validity, discriminant
validity, and responsiveness of the USS were assessed. RESULTS:
Data from 580 men (Trial 1) and 331 women (Trial 2) were
analyzed. Mean age was 65.2 (men) and 47.8 (women); in both
studies, 70% were Caucasian. Correlations of USS scores with
bladder diary variables were small to moderate and higher
among Sum USS than Mean USS. Correlations among the USS
with OAB-q, Perception of Bladder Condition (PBC), and Per-
ception of Treatment Beneﬁt (PTB) were moderate to strong and
higher with Sum USS. Both the Mean and Sum USS signiﬁcantly
discriminated (all p < 0.001) among all bladder diary variables
(except men, nocturia and UUI) when grouped as improved/not
improved as well as by the OAB-q, PBC, and PTB. Effect sizes for
men and women respectively were -0.52 and -1.09 for Mean
USS and -0.72 and -1.36 for Sum USS. CONCLUSIONS: The
USS is a valid and highly responsive measure of urinary urgency
in women with OAB and men with OAB-BPH.
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OBJECTIVES: To evaluate the psychometric properties of 10
language versions of the King’s Health Questionnaire (KHQ).
METHODS: The KHQ, a 21-item instrument to assess health-
related quality of life in patients with urinary incontinence and
OAB, has been translated into numerous languages. Data from
a multicenter, randomized, double-blind, placebo- and active-
controlled trial of fesoterodine for OAB patients were analyzed to
assess the psychometric properties of the KHQ in ten languages.
Patients completed the KHQ at Baseline (BL) and Week 12 of
treatment and bladder diaries for 3 days before each visit. Mean
BL scores, Cronbach alphas, and subscale change scores were
calculated for the KHQ in each language. RESULTS: Data from
839 patients were analyzed (Australia = 104; Bulgaria = 58;
Czech Republic = 55; Estonia = 59; Germany = 59; New Zealand
(NZ) = 82; Poland = 84; Romania = 66; Russia = 81; and South
Africa = 191). Mean age was 56.7  13.9 years; 80% were
female; 96% were white. BL subscale scores ranged from 16.8
(General Health Perceptions [GHP]; NZ English) to 83.6 (Impact
on Life; German). Six of 7 multi-item KHQ subscales (Role
Abstracts A655
Limitations, Physical Limitations, Social Limitations, Personal
Relationships, Emotions, and Severity Measures; exception:
Sleep/energy) generally demonstrated adequate internal consis-
tency reliability at BL for all languages except Bulgarian, Czech,
Estonian, and Russian. Cronbach alphas at follow-up ranged
from 0.50 (Physical Limitations; Russian) to 0.96 (Personal Rela-
tionships; Polish). Concurrent validity was established in all lan-
guages with moderate to strong correlations with other PRO
measures (Treatment Beneﬁt Scale, Satisfaction question) and
small to moderate correlations with bladder diary variables. All
subscales, except GHP, were responsive to treatment in all lan-
guages. CONCLUSIONS: The KHQ is a psychometrically valid
outcomes measure in Australian English, German, New Zealand
English, Polish, Romanian, Russian, and South African English.
PUK20
VALIDATION OFTHE SPANISHVERSION OFTHE PELVIC
ORGAN PROLAPSE/URINARY INCONTINENCE SEXUAL
QUESTIONNAIRE-SHORT FORM (PISQ-12)
Rebollo P1, Espuña PM2, Puig-Clota M2, Gonzalez A2, Zardain PC1
1BAP Health Outcomes Research, Oviedo, Asturias, Spain, 2Institut
Clínic de Ginecología Obstetricia i Neonatología. Hospital Clínic.
Universidad de Barcelona, Barcelona, Spain
OBJECTIVES: To translate and to validate the short form of
Pelvic Organ Prolapse /Urinary Incontinence Sexual Question-
naire (PISQ-12) for its use in Spain. METHODS: Forty-nine
women who visited a specialized urogynecological unit with
symptoms of pelvic ﬂoor dysfunction were included. Patients
ﬁlled in the Spanish version of the questionnaire to validate
(PISQ-12), the International Consultation on Incontinence
Urinary Incontinence Questionnaire Short Form (ICIQ-UI SF);
the Female Sexual Function Questionnaire (FSM) and the
Bladder Control Self-assessment Questionnaire (CACV). Feasi-
bility, reliability and validity of the new questionnaire were
evaluated. RESULTS: Feasibility: 99.83% of the sample
answered all the items (only one patient did not answer one of
the items); average administration time was 3.5 (1.5) minutes.
Reliability: Cronbach’s alpha was 0.829. Validity: PISQ-12 cor-
relation coefﬁcient with FSM was 0.71; with ICIQ-UI-SF it was
-0.038; with the CACV “symptoms” dimension the correlation
was -0.30 and with the “discomfort” dimension it was -0.40.
The existence of the same three dimensions of the PISQ-12
original version in the adapted Spanish questionnaire was
checked through a factorial analysis. The score in PISQ-12 was
worse (lower) in the case of women with Overactive Bladder
symptoms and discomfort measured with the CACV question-
naire and in women with sexual dysfunction measured with
FSM. PISQ-12 is an instrument with the appropriate psychomet-
ric characteristics to evaluate sexual function in women with
pelvic ﬂoor problems. CONCLUSIONS: The PISQ-12 is the ﬁrst
validated questionnaire in Spain for the evaluation of the sexual
function in women with Pelvic Organ Prolapse and/or Urinary
Incontinence. This questionnaire will be useful in the assessment
of the outcomes of different treatments of pelvic organ prolapse.
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OBJECTIVES: Evaluate the content validity of the Subject’s
Assessment of Condition (SAC), Subject’s Assessment of Treat-
ment Satisfaction (SATS), King’s Health Questionnaire (KHQ)
and International Consultation on Incontinence Questionnaire–
Short Form (ICIQ-SF) in overactive bladder (OAB) patients.
METHODS: Cognitive interviews were conducted with adult
OAB patients. Patients provided consent, completed the SAC,
SATS, KHQ and ICIQ-SF and one-on-one interviews to provide
feedback about each questionnaire. The SAC and SATS are single
item questions related to bladder problems and treatment satis-
faction. The KHQ is a 21-item disease-speciﬁc instrument assess-
ing health-related quality of life and incontinence severity. The
ICIQ-SF is a 3-item, incontinence-speciﬁc questionnaire. Content
and descriptive analyses were performed. RESULTS: Twentyfour
patients (18 women, 6 men), mean age 59.0 _ 10.8 years, com-
pleted the study; 100% Caucasian. All questionnaires were
acceptable and understood by participants. In general, the KHQ
covered the key aspects of how OAB impacts patients’ daily lives.
A few minor inconsistencies were noted: 1) “Shopping” was not
considered by some to be a “household task”; “cleaning” did not
resonate with men; 2) “Limiting social life” and “limit ability to
visit friends” and “depressed” and “feel bad about yourself”
were perceived as redundant while “depressed” and “anxious or
nervous” were perceived by some to be too strong; and 3) Some
women were unsure if the intended meaning of the item “change
your underclothes when they get wet” was about changing wet
underwear or frequency of incontinence. A few inconsistencies
were also noted for the ICIQ-SF: The amount of urine leaked
item was problematic for women as “amount” frequently varies,
and while lifting heavy objects and “during sexual relations”
were suggested as questions to ask when leakage occurs. CON-
CLUSIONS: The SAC, SATS, KHQ, and ICIQ-SF were under-
stood by patients with OAB. Minor suggestions for improvement
were made for the KHQ and ICIQ-SF.
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OBJECTIVES: To develop brief patient evaluation or satisfaction
surveys, knowing patients’ priorities can be helpful in deciding
which aspects of care should be tracked and to improve the
quality of the cares. On the other hand it is necessary to identify
the characteristics of the patients and the own medical services
that are inﬂuencing the patient satisfaction. The aims of the study
were to assess the patient’s satisfaction in two haemodialysis
units, one public, the Hospital Universitario Central de Asturias
Unit, and the arranged health centre Cruz Roja Unit, and to
analyze which variables were associated to it. METHODS: All
patients (N = 140) were interviewed by a psychologist that
belongs to Nephrology Unit with SERVQHOS survey, previously
used in our country and that measures the satisfaction with
twenty aspects of the Unit. Patient’s HRQOL was evaluated,
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